RT Journal Article
SR Electronic
T1 Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models
JF ERJ Open Research
JO erjor
FD European Respiratory Society
SP 00028-2015
DO 10.1183/23120541.00028-2015
VO 1
IS 2
A1 Roland Hubaux
A1 Fabian Vandermeers
A1 Jean-Philippe Cosse
A1 Cecilia Crisanti
A1 Veena Kapoor
A1 Steven M. Albelda
A1 Céline Mascaux
A1 Philippe Delvenne
A1 Pascale Hubert
A1 Luc Willems
YR 2015
UL http://openres.ersjournals.com/content/1/2/00028-2015.abstract
AB With 5-year survival rates below 5%, small cell lung carcinoma (SCLC) has very poor prognosis and requires improved therapies. Despite an excellent overall response to first-line therapy, relapses are frequent and further treatments are disappointing. The goal of the study was to improve second-line therapy of SCLC.The effect of chemotherapeutic agents was evaluated in cell lines (apoptosis, reactive oxygen species, and RNA and protein expression) and in mouse models (tumour development).We demonstrate here that valproic acid, a histone deacetylase inhibitor, improves the efficacy of a second-line regimen (vindesine, doxorubicin and cyclophosphamide) in SCLC cells and in mouse models.Transcriptomic profiling integrating microRNA and mRNA data identifies key signalling pathways in the response of SCLC cells to valproic acid, opening new prospects for improved therapies.Valproic acid improves second-line regimen of SCLC response in preclinical models http://ow.ly/Rsyd8